Risk minimization practices for pregnancy prevention: understanding risk, selecting tools
- 5 September 2006
- journal article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 16 (3), 337-348
- https://doi.org/10.1002/pds.1312
Abstract
According to the March of Dimes, approximately 4% (1/28) of babies are born in the US each year with a birth defect. For the majority of birth defects the etiology is unknown, although chemicals, including drug exposures, probably account for less than 1% of all birth defects. The identification of potential human teratogenicity during drug development is important because drug‐induced adverse fetal effects are potentially preventable with the application of risk assessment strategies and risk minimization tools and programs to minimize risk of pregnancy exposure while preserving access to drug benefits; risk assessment and risk minimization together comprise risk management. It is important that risk minimization programs intended to limit fetal exposure use a consistent approach and are tailored to the product‐specific risk concerns in order to optimize the benefit–risk balance for a particular drug. This paper highlights general considerations in developing specific risk minimization programs to prevent fetal drug exposure including the relative advantages and disadvantages of each strategy. Published in 2006 by John Wiley and Sons Ltd.Keywords
This publication has 18 references indexed in Scilit:
- Trends in Congenital Malformations, 1974–1999: Effect of Prenatal Diagnosis and Elective TerminationObstetrics & Gynecology, 2004
- Prescription drug use in pregnancyAmerican Journal of Obstetrics and Gynecology, 2004
- New contraceptive methods: update 2003Current Opinion in Pediatrics, 2003
- Addressing Environmentally Caused Human Birth DefectsPediatrics in Review, 2001
- Contraindicated medications dispensed with cisapride: temporal trends in relation to the sending of ?dear doctor? lettersPharmacoepidemiology and Drug Safety, 2001
- Contraindicated Use of CisaprideJAMA, 2000
- Chemically Induced Birth DefectsPublished by Informa UK Limited ,2000
- Contraceptive failure rates: new estimates from the 1995 National Survey of Family Growth.Family Planning Perspectives, 1999
- Drugs in PregnancyNew England Journal of Medicine, 1998
- Angiotensin‐converting enzyme inhibitors, an embryopathic class of drugs with unique properties: Information for clinical teratology counselorsTeratology, 1991